Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ALL Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest Videos Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Acute Lymphoblastic Leukemia (ALL) Channel

Alongside a world-leading Editorial Board, VJHemOnc can provide all of the latest updates you need in ALL. Speaking directly with the experts at international congresses, The ALL Channel brings you video interviews, podcasts, roundtable discussions and more.

As well as therapy updates including CAR-T, antibody-drug conjugates and chemotherapy, The ALL Channel covers advances in transplantation, measurable residual disease (MRD), managing therapy toxicities, diagnosing ALL and more.

Conferences

SOHO 2025
EHA 2025
ISAL 2025
CAR-T Meeting 2025
ASH 2024
SOHO 2024
1:38
How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga • 11 Sep 2025
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
View All Videos
3:30
The durability of responses with CAR T-cell therapy in ALL and predictors of long-term remission
Jae Park • 18 Jun 2025
2:47
Treating ALL in community settings without access to sophisticated MRD testing
Jae Park • 18 Jun 2025
4:51
Long-term data on obe-cel and its potential as a definitive treatment for adult R/R B-ALL
Jae Park • 18 Jun 2025
4:20
ALLG BM12 CAST: post-transplant cyclophosphamide for GvHD prophylaxis in stem cell transplantation
David Curtis • 15 Jun 2025
View All Videos
3:16
A Phase III trial incorporating inotuzumab ozogamicin into frontline ALL treatment for young adults
Wendy Stock • 10 Mar 2025
1:59
Using CRISPR/Cas9 to identify potential therapeutic targets in acute leukemia PDX cells
Binje Vick • 18 Mar 2025
2:07
Targeting mitochondrial metabolism in hematopoietic stem cells for the treatment of acute leukemias
Els Mansell • 21 Mar 2025
1:28
Advice for community physicians when managing young adults with ALL
Wendy Stock • 10 Mar 2025
View All Videos
2:39
The status of CAR T-cell therapy in Brazil and barriers to access
Nelson Hamerschlak • 7 Feb 2025
1:40
The treatment of acute lymphoblastic leukemia in Brazil
Nelson Hamerschlak • 7 Feb 2025
2:28
Hospital exemption as a route for patient access to CAR-T therapy in Spain
Manel Juan Otero • 3 Feb 2025
5:24
Results of the pivotal CART19-BE-02 trial, a multicenter trial of var-cel for adult R/R B-ALL
Valentín Ortiz-Maldonado • 7 Feb 2025
View All Videos
1:46
Reducing the intensity of conditioning chemotherapy to promote GvL and reduce GvHD
Issa Khouri • 8 Dec 2024
2:22
NGS-MRD is predictive of PFS in patients with R/R ALL treated with brexu-cel
Jae Park • 16 Dec 2024
2:03
Outcomes of inotuzumab/blinatumomab-based treatment in pts with Ph- ALL & myeloid-type mutations
Jayastu Senapati • 7 Dec 2024
1:28
MRD monitoring for Ph+ ALL in the GIMEMA ALL2820 trial
Sabina Chiaretti • 7 Dec 2024
View All Videos
2:19
The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL
Farhad Ravandi • 7 Sep 2024
1:26
Incidence and risk factors associated with VOD/SOS in younger vs older adults after SCT
Partow Kebriaei • 4 Sep 2024
0:52
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
Eduardo Rego • 6 Sep 2024
1:08
The prognostic value of MRD and PB versus BM measurements in T-ALL
Josep-Maria Ribera • 4 Sep 2024
View All Videos

Topics

Transplant
CAR-T & Cellular Therapy
MRD
Immuno-Oncology
Trial Updates
Treatment
1:38
How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga • 11 Sep 2025
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
1:15
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
Bijal Shah • 4 Sep 2025
1:45
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand • 4 Sep 2025
View All Videos
1:38
How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga • 11 Sep 2025
2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
1:15
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
Bijal Shah • 4 Sep 2025
View All Videos
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
1:20
The current role of CAR T-cell therapy in high-risk B-ALL
Bijal Shah • 4 Sep 2025
2:47
Treating ALL in community settings without access to sophisticated MRD testing
Jae Park • 18 Jun 2025
3:30
The role of MRD in risk stratification and treatment decisions for adult ALL
Jae Park • 18 Jun 2025
View All Videos
1:38
How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga • 11 Sep 2025
2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
1:15
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
Bijal Shah • 4 Sep 2025
View All Videos
1:45
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand • 4 Sep 2025
3:48
Five-year analysis of the ZUMA-3 trial: the efficacy of brexu-cel in R/R B-ALL
Bijal Shah • 4 Sep 2025
4:20
ALLG BM12 CAST: post-transplant cyclophosphamide for GvHD prophylaxis in stem cell transplantation
David Curtis • 15 Jun 2025
1:20
Comparative efficacy of GIMEMA LAL1913 chemotherapy protocol versus standard arm of E1910 in ALL
Alfonso Piciocchi • 24 Jun 2025
View All Videos
1:38
How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga • 11 Sep 2025
1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
View All Videos
The content of VJHemOnc is intended for healthcare professionals